Profusa Reports Catastrophic Losses, Zero Revenue, and Imminent Nasdaq Delisting Amid Massively Dilutive Financing and Equity Acquisition

summarizeSummary

Profusa's 10-K reveals a dramatic increase in net losses, zero revenue, and an auditor's going concern warning, compounded by ongoing Nasdaq delisting threats and reliance on highly dilutive equity financing and a massively dilutive acquisition LOI.

check_boxKey Events

• Severe Financial Deterioration

  Net loss surged to $35.8 million in 2025 from $9.2 million in 2024, with revenue dropping to zero. Cash used in operations increased significantly to $16.2 million, and the company reported an accumulated deficit of $160.8 million.

• Going Concern & Nasdaq Delisting Imminent

  The company's auditor expressed substantial doubt about its ability to continue as a going concern. Profusa failed to regain compliance with Nasdaq's minimum bid price and market value requirements by March 10, 2026, despite a 1-for-75 reverse stock split on February 9, 2026. Its securities are subject to delisting, with an appeal hearing scheduled for April 21, 2026.

• Highly Dilutive Financing Activities

  Profusa drew $10.3 million from an Equity Line of Credit (ELOC) through December 31, 2025. Post-period, it issued 321,439 shares for $0.8 million under the ELOC and 2,696,907 shares to settle $1.9 million in PIPE notes. A related-party convertible note for $1.9 million was converted into 2,460,257 shares at $0.76 per share, and a new $0.6 million PIPE note with a warrant for 1,111,111 shares at $0.50 exercise price was issued on April 2, 2026.

• Massively Dilutive Equity Acquisition Proposed

  The company entered a non-binding Letter of Intent on March 31, 2026, to acquire Bio Insights' PanOmics assay for $30.0 million, payable entirely through the issuance of equity securities. This represents an extreme dilution risk, as the acquisition value is approximately 33 times the company's current market capitalization.

auto_awesomeAnalysis

Profusa, a micro-cap company, has reported a dire financial situation in its latest 10-K filing, revealing a significant increase in net losses and a complete absence of revenue for 2025. The company's ability to continue as a going concern is in substantial doubt, and it faces imminent delisting from Nasdaq after failing to meet multiple listing requirements, despite a recent reverse stock split. To address its severe cash burn, Profusa has engaged in highly dilutive financing activities, including drawing on an Equity Line of Credit and converting substantial related-party debt into common stock at low prices. Furthermore, a non-binding Letter of Intent to acquire Bio Insights' PanOmics assay for $30.0 million, payable entirely in equity, signals an extraordinary level of potential dilution for existing shareholders, far exceeding the company's current market capitalization. The disclosure of material weaknesses in internal financial controls adds another layer of significant risk, indicating fundamental operational challenges.